<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35608635</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1173</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete</Title>
          <ISOAbbreviation>Hautarzt</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00105-022-05004-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Atopic dermatitis is a common chronic inflammatory skin disease and has a major impact on patient's quality of life. Janus kinase inhibitors were recently approved for the treatment of atopic dermatitis.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To summarize current data on efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis as well as guidelines for the use in clinical practice.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Summary and assessment of currently available data.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Three Janus kinase inhibitors are approved for the treatment of moderate to severe atopic dermatitis: baricitinib, upadacitinib and abrocitinib. Clinical trials and first real-life data demonstrate rapid and strong reduction of pruritus and clinical signs of atopic dermatitis as well as improvement of patient's quality of life. The safety profile is favorable, although data on long-term safety especially for the treatment of atopic dermatitis patients are still lacking.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Janus kinase inhibitors enrich the therapeutic portfolio for the treatment of atopic dermatitis. When carefully taking into consideration contraindications, side effects, and necessary laboratory controls, they represent a highly effective and safe treatment option for affected patients.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lauffer</LastName>
            <ForeName>Felix</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Biedersteinerstr. 29, 80802, München, Deutschland. felix.lauffer@mri.tum.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biedermann</LastName>
            <ForeName>Tilo</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Biedersteinerstr. 29, 80802, München, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>ger</Language>
        <PublicationTypeList>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Einschätzungen zur Therapie der moderaten bis schweren atopischen Dermatitis mit Januskinaseinhibitoren.</VernacularTitle>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Hautarzt</MedlineTA>
        <NlmUniqueID>0372755</NlmUniqueID>
        <ISSNLinking>0017-8470</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <OtherAbstract Type="Publisher" Language="ger">
        <AbstractText Label="ZUSAMMENFASSUNG" NlmCategory="UNASSIGNED">HINTERGRUND: Die atopische Dermatitis ist eine häufige chronisch entzündliche Hauterkrankung, die mit erheblichem Leidensdruck einhergeht. Januskinaseinhibitoren sind seit Kurzem für die Therapie der atopischen Dermatitis verfügbar.</AbstractText>
        <AbstractText Label="FRAGESTELLUNG" NlmCategory="UNASSIGNED">Es erfolgen eine Zusammenfassung der bisherigen Daten zur Wirksamkeit und Sicherheit von Januskinaseinhibitoren zur Therapie der atopischen Dermatitis sowie Darstellung praktischer Hinweise zum klinischen Einsatz.</AbstractText>
        <AbstractText Label="MATERIAL UND METHODEN" NlmCategory="METHODS">Es werden eine Zusammenfassung und Bewertung der aktuell verfügbaren Datenlage gegeben.</AbstractText>
        <AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED">Drei Januskinaseinhibitoren sind zur Therapie der mittelschweren bis schweren atopischen Dermatitis zugelassen: Baricitinib, Upadacitinib und Abrocitinib. In den Zulassungsstudien und ersten Real-Life-Erfahrungen wurden eine starke und schnelle Reduktion des Juckreizes und der klinischen Zeichen der atopischen Dermatitis sowie positive Effekte auf die Lebensqualität betroffener Personen demonstriert. Das aktuelle Sicherheitsprofil zeigt sich günstig, wobei jedoch Langzeitsicherheitsdaten speziell für den Einsatz bei der atopischen Dermatitis aktuell noch nicht verfügbar sind.</AbstractText>
        <AbstractText Label="SCHLUSSFOLGERUNGEN" NlmCategory="UNASSIGNED">Januskinaseinhibitoren bereichern das therapeutische Spektrum bei der Behandlung der atopischen Dermatitis. Unter Beachtung der Kontraindikationen, Nebenwirkungen und notwendigen Laboruntersuchungen stellen sie eine hocheffektive und sichere Therapieoption für betroffene Patienten dar.</AbstractText>
        <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Abrocitinib</Keyword>
        <Keyword MajorTopicYN="N">Baricitinib</Keyword>
        <Keyword MajorTopicYN="N">Quality of life</Keyword>
        <Keyword MajorTopicYN="N">Safety profile</Keyword>
        <Keyword MajorTopicYN="N">Upadacitinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>11</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35608635</ArticleId>
        <ArticleId IdType="doi">10.1007/s00105-022-05004-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s00105-022-05004-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>Literatur</Title>
        <Reference>
          <Citation>Abraham S, Haufe E, Harder I, Heratizadeh A, Kleinheinz A, Wollenberg A, Weisshaar E, Augustin M, Wiemers F, Zink A, Biedermann T, von Kiedrowski R, Hilgers M, Worm M, Pawlak M, Sticherling M, Fell I, Handrick C, Schakel K, Staubach P, Asmussen A, Schwarz B, Bell M, Neubert K, Effendy I, Bieber T, Homey B, Gerlach B, Tchitcherina E, Stahl M, Schwichtenberg U, Rossbacher J, Buck P, Mempel M, Beissert S, Werfel T, Weidinger S, Schmitt J, group TRs (2020) Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany. Br J Dermatol 183:382–384</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arana Yi C, Tam CS, Verstovsek S (2015) Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol 11:719–733</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon.14.272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bieber T, Simpson EL, Silverberg JI, Thaci D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H, Investigators JC (2021) Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 384:1101–1112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2019380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K (2021) Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 157:1047–1055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2021.3023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd AL, Belkaid Y, Segre JA (2018) The human skin microbiome. Nat Rev Microbiol 16:143–155</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro.2017.157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyerich K, Eyerich S, Biedermann T (2015) The multi-modal immune pathogenesis of atopic eczema. Trends Immunol 36:788–801</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2015.10.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyerich S, Eyerich K, Traidl-Hoffmann C, Biedermann T (2018) Cutaneous barriers and skin immunity: differentiating a connected network. Trends Immunol 39:315–327</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2018.02.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>https://www.arzneimittelleitfaden.de/checklisten-systemtherapie-neurodermitis/ . Zugegriffen: 7. März 2022</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2021/rhb-xeljanz.html . Zugegriffen: 7. März 2022</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.ema.europa.eu/en/news/ema-starts-safety-review-janus-kinase-inhibitors-inflammatory-disorders . Zugegriffen: 7. März 2022</Citation>
        </Reference>
        <Reference>
          <Citation>https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death . Zugegriffen: 7. März 2022</Citation>
        </Reference>
        <Reference>
          <Citation>Langan SM, Irvine AD, Weidinger S (2020) Atopic dermatitis. Lancet 396:345–360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31286-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauffer FBT (2021) Atopisches Ekzem: Störfeuer für eine Dreiecksbeziehung. Dtsch Arztebl 118(24):[24]. https://doi.org/10.3238/PersDerma.2021.06.18.04</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3238/PersDerma.2021.06.18.04</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF, Investigators OS (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1310476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Terres RJA, Watts SD, Chen YF, Simpson EL, Silverberg JI (2020) Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. https://doi.org/10.1080/09546634.2020.1839008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09546634.2020.1839008</ArticleId>
            <ArticleId IdType="pubmed">33222559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL (2020) Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156:1333–1343</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2020.3260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397:2169–2181</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00589-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogner D, Biedermann T, Lauffer F (2022) Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. https://doi.org/10.2340/actadv.v102.1088</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2340/actadv.v102.1088</ArticleId>
            <ArticleId IdType="pubmed">35083493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 396:255–266</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30732-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solimani F, Hilke FJ, Ghoreschi K (2019) Pharmacology of Janus kinase inhibitors. Hautarzt 70:934–941</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00105-019-04509-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volz T, Skabytska Y, Guenova E, Chen KM, Frick JS, Kirschning CJ, Kaesler S, Rocken M, Biedermann T (2014) Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 134:96–104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2013.291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Folster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H (2021) Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 19:151–168</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33491884</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
